Tigermed IPO Initiation: Trade-Offs
Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
418 Views
Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play
Hangzhou Tigermed is a leading China-based CRO company seeking a USD 1 bn H-share listing in Hong Kong. The company was listed on the A-share...
494 Views
SH/SZ Connect Flows: Wuxi Apptec, ZTE, Yili
In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...
259 Views
ECM Weekly (29 Mar 2020) - Wuxi AppTec, Kintor Pharma, Softbank Group-Driven Placements and More!
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We...
359 Views
Wuxi Apptec (药明康德) Proposed USD1.7bn Placement: Liquidity Matters
Wuxi Apptec is planning to sell both A-share and H-share in a private placement to raise up to USD 1.7 billion. The stock has performed well since...
474 Views